Using artificial intelligence to monitor early and intermediate macular degeneration over time
Watches people with early or intermediate macular degeneration with eye scans and artificial intelligence.
Plain-language title generated from the registry record
Registry title: Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Key facts
- Where
- Vienna, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 99 with early or intermediate age-related macular degeneration (AMD) in at least one eye. They will be followed for 24 months with eye scans.
- Age
- 55 to 99 years
- Sex
- All sexes can join.
- Disease stage
- Early or intermediate AMD in at least one eye (drusen larger than 63 µm and/or definite changes in eye pigment, with or without reticular pseudodrusen).
- Earlier treatment
- People who ever had anti-VEGF treatment in the study eye before the start cannot join. No eye surgery in the study eye in the 3 months before the start.
Main reasons for not taking part
- Anti-VEGF treatment in the study eye before the start
- Eye surgery in the study eye within 3 months before the start
- Active macular neovascularization at the start
- Taking drugs known to harm the retina (for example hydroxychloroquine or tamoxifen)
- Refractive error larger than 6 diopters
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 99 years old?
Source: NCT06351670, who can take part
Where in Austria
- Medical University of ViennaVienna, AustriaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Medical University of Vienna
- Trial code
- NCT06351670
- Record updated
- 15 May 2025
- Original description
The goal of this prospective, multinational, multicenter observational study is to to predict conversion of early and intermediate AMD with functional vision to advanced AMD with irreversible loss of vision on an individual-based level over 2 years. The main objectives of this study are:Read full original descriptionShow less
Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression in a Prospective, Multinational, Multicentre Observational Study
The goal of this prospective, multinational, multicenter observational study is to to predict conversion of early and intermediate AMD with functional vision to advanced AMD with irreversible loss of vision on an individual-based level over 2 years. The main objectives of this study are:
* Identify and quantify focal and global alterations in the retina in regard to disease progression. * Assess the individual risk of disease progression in intermediate AMD patients converting to advanced AMD based on imaging. * Specify the course of disease in regard to the sequence of events that lead to the conversion to advanced AMD * Enhance the ability to classify AMD using artificial intelligence in addition to traditional models.
All patients will be followed for 24 months with 6 month intervals to assess clinical changes. Monitoring of disease progression will be performed using the following routine in-vivo imaging procedures:
* Scanning Laser Fundus Photography * Color Fundus Photography (CFP) * Optical Coherence Tomography (OCT) * Optical Coherence Tomography Angiography (OCTA) Patients will be asked for their medical history. Standard ophthalmic examination, as well as a questionnaire on visual function will be carried out.
No intervention will be performed during the study since no treatment is yet available within Europe. As soon as treatment is approved in the EU, patients in this cohort might receive treatment according to availability in their respective country and standard of care. If treatment will be performed, it will be as standard of care outside the study according to each country's standard of care and by EMA label.
Inclusion: Age: 55-99 years old; Early or intermediate AMD in at least one eye (drusen > 63 µm and/or any definite hyper- or hypopigmentary abnormalities with or without reticular pseudodrusen); If both eyes are eligible, both eyes will be included in the cohort study; Clear optical media and adequate pupillary dilation for imaging and functional testing.
Exclusion: Any surgical treatment of the eye within 3 months prior to baseline in the study eye; History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio > 0.9; Any concurrent intraocular condition in the study eye (e.g. advanced cataract or moderate/severe diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition; Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery and YAG capsulotomy) during the study period; Intake of drugs known to cause retinal toxicity (e.g. hydroxychloroquine or tamoxifen); History of anti-VEGF treatment in the study eye before baseline; History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the study eye; Refractive error larger than 6 diopters. In case of pseudophakia or refractive surgery: History of refractive error larger than 6 diopters; Presence of corneal decompensation, haze or scarring with an impact on BCVA; Presence of active macular neovascularization at baseline.